Evidence map›Paper›PMID 28008331›Full record

ArticleFrontiers in immunology2016

A Meningococcal Outer Membrane Vesicle Vaccine Incorporating Genetically Attenuated Endotoxin Dissociates Inflammation from Immunogenicity.

David J Dowling, Holly Sanders, Wing Ki Cheng, Sweta Joshi, Spencer Brightman, Ilana Bergelson, Carlo Pietrasanta, Simon D van Haren, Sandra van Amsterdam, Jeffrey Fernandez and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Development of a Promising Bivalent Vaccine AgainstExploration (Beijing, China) · 2025
    Article
  5. Article
  6. Article
  7. Vaccine adjuvants for infectious disease in the clinic.Bioengineering & translational medicine · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Frontiers in immunology · 2021
    Review
  13. Review
  14. OMV Vaccines and the Role of TLR Agonists in Immune Response.International journal of molecular sciences · 2020
    Review
  15. Review
  16. Article
  17. Outer membrane vesicles for vaccination and targeted drug delivery.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

David J DowlingDepartment of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Holly SandersJanssen Vaccines and Prevention B.V. , Leiden , Netherlands.
Wing Ki ChengDepartment of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Sweta JoshiDepartment of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Spencer BrightmanDepartment of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Ilana BergelsonDepartment of Medicine, Division of Infectious Diseases, Boston Children's Hospital , Boston, MA , USA.
Carlo PietrasantaDepartment of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA; Neonatal Intensive Care Unit, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Simon D van HarenDepartment of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Sandra van AmsterdamJanssen Vaccines and Prevention B.V. , Leiden , Netherlands.
Jeffrey FernandezJanssen Research and Development, LLC , Spring House, PA , USA.
Germie P J M van den DobbelsteenJanssen Vaccines and Prevention B.V. , Leiden , Netherlands.
Ofer LevyDepartment of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Boston Children's Hospital · USJanssen (Netherlands) · NLHarvard University · USJanssen (United States) · USUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGroup B

methodsOMVs from wild type- and inactivated

resultsΔ

conclusionA meningococcal vaccine comprised of attenuated LPS-based OMVs with a limited inflammatory profile

Indexed as

dendritic cellsgroup B meningococcinewbornouter membrane vesiclesvaccine

Identifiers

PMID28008331
PMCPMC5143884
OpenAlexW2560595878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.